Back to Markets
Stocks● Neutral
Vitrafy Targets US Blood Network as Glycerol Tech Ends 2027
Vitrafy deploys two units at Vitalant as glycerol-based red blood cell freezing nears 2027 phase-out, threatening US blood supply network.
Continue with
Vitrafy Life Sciences (ASX: VFY) has signed a partnership with US blood network Vitalant Innovation Centre to deploy its next-generation cryopreservation ecosystem for red blood cells. The arrangement directly targets an urgent market gap created by the planned discontinuation of glycerol-based freezing technologies in 2027.
Without a successor at scale, the US blood network risks losing the ability to stockpile red blood cells for rare blood types and mass-casualty events. Vitalant collects about 10% of the nation's blood supply annually through 125 donation centres and 60,000 blood drives, serving roughly 900 hospitals.
Glycerol Phase-Out by 2027 Creates Industry Urgency
Glycerol-based cryopreservation has been the industry standard for freezing red blood cells. Manufacturers are expected to stop supporting it by 2027. No replacement has been validated at commercial scale.
Vitrafy’s ecosystem uses a different freezing method that avoids the toxic cryoprotectants and complex deglycerolization steps required by legacy systems. The technology was previously tested in a US Army platelets study, which Vitrafy managing director Brent Owens cited as the foundation for civilian blood network interest.
“We are really excited to actively address an issue of national significance with one of the leading blood market participants in the US,” Owens said. “The recognition of our cryopreservation ecosystem as the next-generation solution to this crisis reinforces our belief that we are securing meaningful market traction and creating a pathway to significant commercial scale.”
The 2027 deadline creates a hard stop for the industry. Blood centres that delay switching risk losing access to stockpiled red blood cells for rare blood types and emergency reserves. This gives Vitrafy a defined adoption window, though the transition will require regulatory clearance and capital.
Vitrafy–Vitalant Partnership: From Pilot to Potential Standard
Under the partnership, Vitrafy will deploy two cryopreservation freezing units to Vitalant’s premises in Colorado. The placement will not generate revenue. Vitrafy expects the units to support broader market and government engagement toward a unified response to the glycerol phase-out.